The plant-based biologics market is comprised of plant-derived therapeutics that are an alternative to conventional protein drugs. Some key products in this market include recombinant proteins, monoclonal antibodies, vaccines and antibodies fragments that are produced in plant-based expression systems like tobacco, maize, alfalfa and others. Plant-based biologics offer advantages like low-cost production and scalability. They also help address concerns surrounding the environmental footprint of conventional biologics produced in microbial or animal cell culture systems.
The global plant-based biologics market is estimated to be valued at US$ 15.8 Bn in 2024 and is expected to exhibit a CAGR of 8.2% over the forecast period 2024 to 2031. Key Takeaways: Key players operating in the plant-based biologics market are DSM Nutritional Products, Lycored, Lycored SARL, FutureCeuticals, Vidya Herbs, Allied Biotech Corporation, Avestia Pharma, Xi'an Green Source Co., Ltd., Beijing Gingko Group (BGG), Shaanxi Jiahe Phytochem Co., Ltd. These players are actively focusing on expanding their production capacities and capabilities to cater to the growing demand. Some major opportunities in the Plant-Based Biologics Market Demand include the development of plant-based biologics for treatment of chronic diseases. As environmental concerns regarding conventional production methods rise, there is increased focus on the development of sustainable plant-based expression platforms. Key players are undertaking strategic initiatives like partnerships, mergers and acquisitions for global expansion. For instance, DSM acquired Glycotope GmbH in 2021 to expand its plant-based antibody capabilities. Albany, Oregon has emerged as a key biotech cluster for production of plant-based biologics in North America. Asia Pacific region is also witnessing rising investments in large-scale production facilities owing to low production costs. Market Drivers: The growing emphasis on environmental sustainability is a key factor driving the demand for plant-based biologics. Conventional production methods have high carbon footprint which is boosting research on green alternatives. Rising prevalence of chronic diseases is also propelling the clinical research on plant-based biologics. Support from regulatory agencies in terms of streamlined approval pathways is facilitating market growth. Market Restraints: High capital requirements for setting up large-scale production plants pose challenges, especially for small players. Limited downstream processing capabilities can also hinder scale-up during commercial production. Knowledge gaps regarding regulatory guidelines and intellectual property management practices also act as restraining factors for the plant-based biologics market.
Segment Analysis Therapeutic plant-based biologics dominate the plant-based biologics market currently, accounting for over 50% share. This is because therapeutic plant-based biologics such as antibodies, diagnostic enzymes, blood factors and recombinant vaccines are being increasingly used for treating chronic diseases. Monoclonal antibodies are the largest sub-segment within therapeutic plant-based biologics due to their high specificity and less toxicity. They have shown a lot of promise in treating various types of cancers and autoimmune disorders. Within industrial plant-based biologics, industrial enzymes have the highest share. Industrial enzymes such as amylases, proteases, lipases, cellulases, etc find wide applications in industries like food & beverage processing, textile processing, detergent production, bioethanol production, paper manufacturing, etc. There is a high demand for industrial enzymes from growing industries like food processing, which is driving growth in this sub-segment currently. Regional Analysis North America currently dominates the global Plant-Based Biologics Market Regional Analysis with the largest share. This is attributed to the presence of major players, growing biologics industry and increasing R&D investments in the region. The US accounts for the bulk of the North American plant-based biologics market.
Europe has the second largest share globally due to high adoption of advanced therapies in countries like Germany. However, Asia Pacific is expected to witness the fastest growth during the forecast period due to growing biologics manufacturing industry, rising health expenditure and increasing availability of plant-based recombinant therapeutics in high growth markets of China and India.
Pick the language that you prefer-
About Author-
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.
(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )
